Beranda › Kanker Hati (Karsinoma Hepatoseluler) › Pennsylvania › Philadelphia
Uji klinis Kanker Hati (Karsinoma Hepatoseluler) di Philadelphia, PA
16 studi untuk Kanker Hati (Karsinoma Hepatoseluler) mencari peserta di lokasi sekitar Philadelphia (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #98, Philadelphia
National Liver Cancer Screening Trial
Menerima pesertaFase 4
- University of Pennsylvania, Philadelphia
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Menerima pesertaFase 3
- Research Site, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Menerima pesertaFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Menerima pesertaFase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi jauhnya
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi jauhnya
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
- Thomas Jefferson University, Philadelphia
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Menerima peserta
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Y-90 Treatment Response Using Transarterial Radioembolization
Menerima pesertaFase 2
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Menerima pesertaFase 1/2
- University of Pennsylvania, Philadelphia
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Menerima pesertaFase 1/2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Menerima pesertaFase 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SBRT With Atezo/Bev for HCC
Menerima pesertaFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
Menerima pesertaStudi observasional
- Thomas Jefferson Hospital, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Menerima pesertaFase 4
- Albert Einstein Healthcare Network, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Philadelphia
Uji klinis Kanker Hati (Karsinoma Hepatoseluler) di kota lain
- Houston, TX31 studi
- New York City, NY24 studi
- Dallas, TX19 studi
- Los Angeles, CA19 studi
- Boston, MA18 studi
- Cleveland, OH18 studi
- Chicago, IL16 studi
- Pittsburgh, PA15 studi
- San Francisco, CA14 studi
- Orange, CA14 studi
- Jacksonville, FL14 studi
- San Antonio, TX13 studi
Studi lain di Philadelphia
- Kanker (semua jenis)59 studi
- Kanker Payudara56 studi
- Kanker Paru Non-Sel Kecil51 studi
- Kanker Metastatik46 studi
- Kanker Prostat44 studi
- Kanker Kolorektal44 studi
- Kanker Ovarium44 studi
- Kanker Paru36 studi
- Leukemia Mieloid Akut34 studi
- Gagal Jantung31 studi
- Kanker Endometrium28 studi
- Depresi26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.